Rh D Immune Globulin Administration After Abortion or Pregnancy Loss at Less Than 12 Weeks of Gestation.

IF 8.3 2区材料科学 Q1 MATERIALS SCIENCE, MULTIDISCIPLINARY

ACS Applied Materials & Interfaces Pub Date : 2024-09-10 DOI:10.1097/AOG.0000000000005733

引用次数: 0

Abstract

This Clinical Practice Update provides revised guidance on Rh testing and Rh D immune globulin administration for individuals undergoing abortion or experiencing pregnancy loss at less than 12 0/7 weeks of gestation. This document updates Practice Bulletin No. 225, Medication Abortion Up to 70 Days of Gestation (Obstet Gynecol 2020;136:e31-47); Practice Bulletin No. 200, Early Pregnancy Loss (Obstet Gynecol 2018;132:e197-207); and Practice Bulletin No. 181, Prevention of Rh D Alloimmunization (Obstet Gynecol 2017;130:e57-70).

查看原文本刊更多论文

妊娠不足 12 周的流产或妊娠失败后注射 Rh D 免疫球蛋白。

本《临床实践更新》为妊娠不足 12 0/7 周时进行人工流产或妊娠流产的患者提供了 Rh 检测和 Rh D 免疫球蛋白注射的修订指南。本文件更新了第225号实践公告《妊娠70天以内的药物流产》（Obstet Gynecol 2020;136:e31-47）、第200号实践公告《早期妊娠丢失》（Obstet Gynecol 2018;132:e197-207）和第181号实践公告《Rh D同种免疫的预防》（Obstet Gynecol 2017;130:e57-70）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Materials & Interfaces 工程技术-材料科学：综合

CiteScore

16.00

自引率

6.30%

发文量

4978

审稿时长

1.8 months

期刊介绍： ACS Applied Materials & Interfaces is a leading interdisciplinary journal that brings together chemists, engineers, physicists, and biologists to explore the development and utilization of newly-discovered materials and interfacial processes for specific applications. Our journal has experienced remarkable growth since its establishment in 2009, both in terms of the number of articles published and the impact of the research showcased. We are proud to foster a truly global community, with the majority of published articles originating from outside the United States, reflecting the rapid growth of applied research worldwide.